Title |
The development of bispecific antibodies and their applications in tumor immune escape
|
---|---|
Published in |
Experimental Hematology & Oncology, May 2017
|
DOI | 10.1186/s40164-017-0072-7 |
Pubmed ID | |
Authors |
Xiaolong Zhang, Yuanyuan Yang, Dongmei Fan, Dongsheng Xiong |
Abstract |
During the past two decades, a great evolution of bispecific antibodies (BsAbs) for therapeutic applications has been made. BsAbs can bind simultaneously two different antigens or epitopes, which leads to a wide range of applications including redirecting T cells or NK cells to tumor cells, blocking two different signaling pathways, dual targeting of different disease mediators, and delivering payloads to targeted sites. Aside from approved catumaxomab (anti-CD3 and anti-EpCAM) and blinatumomab (anti-CD3 and anti-CD19), many more BsAbs are now in various phases of clinical development. Here, this review focus on the development of bispecific antibodies and their applications in tumor immune escape. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | <1% |
Unknown | 140 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 27 | 19% |
Student > Bachelor | 22 | 16% |
Other | 16 | 11% |
Student > Ph. D. Student | 16 | 11% |
Student > Master | 14 | 10% |
Other | 16 | 11% |
Unknown | 30 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 33 | 23% |
Agricultural and Biological Sciences | 19 | 13% |
Medicine and Dentistry | 18 | 13% |
Immunology and Microbiology | 15 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
Other | 18 | 13% |
Unknown | 31 | 22% |